TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. doi:10.1016/j.cell.2011.02.013. PMID:21376230
   PubMed Web of Science ®Google Scholar
• Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, Chastain M, Gorski KS, Anderson A, Chou J, et al. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. J Clin Oncol. 2016;34:2619–26. doi:10.1200/JCO.2016.67.1529. PMID:27298410
   PubMed Web of Science ®Google Scholar
• Guarinos C, Juarez M, Egoavil C, Rodríguez-Soler M, Pérez-Carbonell L, Salas R, Cubiella J, Rodríguez-Moranta F, de-Castro L, Bujanda L, et al. Prevalence and characteristics of MUTYH-associated polyposis in patients with multiple adenomatous and serrated polyps. Clin Cancer Res. 2014;20:1158–68. doi:10.1158/1078-0432.CCR-13-1490. PMID:24470512
   PubMed Web of Science ®Google Scholar
• Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6:e1792. doi:10.1038/cddis.2015.162. PMID:26086965
   PubMed Web of Science ®Google Scholar
• Quereux G, Pandolfino MC, Knol AC, Khammari A, Volteau C, Nguyen JM, Dreno B. Tissue prognostic markers for adoptive immunotherapy in melanoma. Eur J Dermatol. 2007;17:295–301. PMID:17540635
   PubMed Web of Science ®Google Scholar
• Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory Pathways in Immunotherapy for Cancer. Annu Rev Immunol. 2016;34:539–573. doi:10.1146/annurev-immunol-032414-112049. PMID:26927206
   PubMed Web of Science ®Google Scholar
• Kyi C, Postow MA. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy. 2016;8:821–37. doi:10.2217/imt-2016-0002. PMID:27349981
   PubMed Web of Science ®Google Scholar
• Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015;75:2139–45. doi:10.1158/0008-5472.CAN-15-0255. PMID:25977340
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–89. doi:10.1038/nature10673. PMID:22193102
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–30. doi:10.1038/nature21349. PMID:28102259
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Lichty BD, Bell JC. Oncolytic Viruses: Therapeutics With an Identity Crisis. EBioMedicine. 2016;9:31–36. doi:10.1016/j.ebiom.2016.06.046. PMID:27407036
   PubMed Web of Science ®Google Scholar
• Niemann J, Kuhnel F. Oncolytic viruses: adenoviruses. Virus Genes. 2017;53(5):700–06. doi:10.1007/s11262-017-1488-1. PMID:28702840
   PubMed Web of Science ®Google Scholar
• Li X, Wang P, Li H, Du X, Liu M, Huang Q, Wang Y, Wang S. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model. Clin Cancer Res. 2017;23:239–49. doi:10.1158/1078-0432.CCR-16-0477. PMID:27435398
   PubMed Web of Science ®Google Scholar
• Tahtinen S, Gronberg-Vaha-Koskela S, Lumen D, Merisalo-Soikkeli M, Siurala M, Airaksinen AJ, Vähä-Koskela M, Hemminki A. Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor. Cancer Immunol Res. 2015;3:915–25. doi:10.1158/2326-6066.CIR-14-0220-T. PMID:25977260
   PubMed Web of Science ®Google Scholar
• Woller N, Gurlevik E, Fleischmann-Mundt B, Schumacher A, Knocke S, Kloos AM, Saborowski M, Geffers R, Manns MP, Wirth TC, et al. Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. Mol Ther. 2015;23:1630–40. doi:10.1038/mt.2015.115. PMID:26112079
   PubMed Web of Science ®Google Scholar
• Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, Tähtinen S, Oksanen M, Heiskanen R, Pesonen S, et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res. 2013;19:2734–44. doi:10.1158/1078-0432.CCR-12-2546. PMID:23493351
   PubMed Web of Science ®Google Scholar
• Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic Viruses in Cancer Treatment: A Review. JAMA Oncol. 2017;3:841–49. doi:10.1001/jamaoncol.2016.2064. PMID:27441411
   PubMed Web of Science ®Google Scholar
• Seymour LW, Fisher KD. Oncolytic viruses: finally delivering. Br J Cancer. 2016;114:357–61. doi:10.1038/bjc.2015.481. PMID:26766734
   PubMed Web of Science ®Google Scholar
• Koski A, Bramante S, Kipar A, Oksanen M, Juhila J, Vassilev L, Joensuu T, Kanerva A, Hemminki A. Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues. Mol Ther. 2015;23:1641–52. doi:10.1038/mt.2015.125. PMID:26156245
   PubMed Web of Science ®Google Scholar
• Bommareddy PK, Patel A, Hossain S, Kaufman HL. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. Am J Clin Dermatol. 2017;18:1–15. doi:10.1007/s40257-016-0238-9. PMID:27988837
   PubMed Web of Science ®Google Scholar
• Fonteneau JF, Achard C, Zaupa C, Foloppe J, Erbs P. Oncolytic immunotherapy: The new clinical outbreak. Oncoimmunology. 2016;5:e1066961. doi:10.1080/2162402X.2015.1066961. PMID:26942085
   PubMed Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170:1109–19 e1110. doi:10.1016/j.cell.2017.08.027. PMID:28886381
   PubMed Web of Science ®Google Scholar
• Tahtinen S, Kaikkonen S, Merisalo-Soikkeli M, Grönberg-Vähä-Koskela S, Kanerva A, Parviainen S, Vähä-Koskela M, Hemminki A. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PLoS One. 2015;10:e0131242. doi:10.1371/journal.pone.0131242. PMID:26107883
   PubMed Web of Science ®Google Scholar
• Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, et al. Adenoviral Delivery of Tumor Necrosis Factor-alpha and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma. Mol Ther. 2016;24:1435–43. doi:10.1038/mt.2016.137. PMID:27357626
   PubMed Web of Science ®Google Scholar
• Havunen R, Siurala M, Sorsa S, Grönberg-Vähä-Koskela S, Behr M, Tähtinen S, Santos JM, Karell P, Rusanen J, Nettelbeck DM, et al. Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy. Mol Ther Oncolytics. 2017;4:77–86. doi:10.1016/j.omto.2016.12.004. PMID:28345026
   PubMed Web of Science ®Google Scholar
• Siurala M, Bramante S, Vassilev L, Hirvinen M, Parviainen S, Tähtinen S, Guse K, Cerullo V, Kanerva A, Kipar A, et al. Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma. Int J Cancer. 2015;136:945–54. doi:10.1002/ijc.29048. PMID:24975392
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27:5763–71. doi:10.1200/JCO.2009.24.3675. PMID:19884534
   PubMed Web of Science ®Google Scholar
• Quetglas JI, Labiano S, Aznar MA, Bolaños E, Azpilikueta A, Rodriguez I, Casales E, Sánchez-Paulete AR, Segura V, Smerdou C, et al. Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade. Cancer Immunol Res. 2015;3:449–54. doi:10.1158/2326-6066.CIR-14-0216. PMID:25691326
   PubMed Web of Science ®Google Scholar
• Shim KG, Zaidi S, Thompson J, Kottke T, Evgin L, Rajani KR, Schuelke M, Driscoll CB, Huff A, Pulido JS, et al. Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy. Mol Ther. 2017;25:962–75. doi:10.1016/j.ymthe.2017.01.023. PMID:28237836
   PubMed Web of Science ®Google Scholar
• Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umansky V, Nettelbeck DM, Weichert W, et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther. 2014;22:1949–1959. doi:10.1038/mt.2014.160. PMID:25156126
   PubMed Web of Science ®Google Scholar
• Moesta AK, Cooke K, Piasecki J, Mitchell P, Rottman JB, Fitzgerald K, Zhan J, Yang B, Le T, Belmontes B, et al. Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte-Associated Protein Blockade. Clin Cancer Res. 2017;23:6190–202. doi:10.1158/1078-0432.CCR-17-0681. PMID:28706012
   PubMed Web of Science ®Google Scholar
• Pennisi M. A mathematical model of immune-system-melanoma competition. Comput Math Methods Med. 2012;2012:850754. doi:10.1155/2012/850754. PMID:22701144
   PubMedGoogle Scholar
• Cerullo V, Diaconu I, Romano V, Hirvinen M, Ugolini M, Escutenaire S, Holm SL, Kipar A, Kanerva A, Hemminki A. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol Ther. 2012;20:2076–86. doi:10.1038/mt.2012.137. PMID:22828500
   PubMed Web of Science ®Google Scholar
• Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, Gatalica Z, Reddy S, Kleiner D, Fishbein T, Johnson L, et al. Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. Cancer Immunol Res. 2016;4:419–30. doi:10.1158/2326-6066.CIR-15-0110. PMID:26968206
   PubMed Web of Science ®Google Scholar
• Rathore AS, Kumar S, Konwar R, Makker A, Negi MP, Goel MM. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast. Indian J Med Res. 2014; 140:361–9. PMID:25366203
   PubMed Web of Science ®Google Scholar
• Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea AD, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7:13587–98. doi:10.18632/oncotarget.7277. PMID:26871470
   PubMed Web of Science ®Google Scholar
• Linardakis E, Bateman A, Phan V, Ahmed A, Gough M, Olivier K, Kennedy R, Errington F, Harrington KJ, Melcher A, et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res. 2002;62:5495–504. PMID:12359759
   PubMed Web of Science ®Google Scholar
• Bianchi V, Bulek A, Fuller A, Lloyd A, Attaf M, Rizkallah PJ, Dolton G, Sewell AK, Cole DK. A Molecular Switch Abrogates Glycoprotein 100 (gp100) T-cell Receptor (TCR) Targeting of a Human Melanoma Antigen. J Biol Chem. 2016;291:8951–59. doi:10.1074/jbc.M115.707414. PMID:26917722
   PubMed Web of Science ®Google Scholar
• Capasso C, Magarkar A, Cervera-Carascon V, Fusciello M, Feola S, Muller M, Garofalo M, Kuryk L, Tähtinen S, Pastore L, et al. A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma. Oncoimmunology. 2017;6:e1319028. doi:10.1080/2162402X.2017.1319028. PMID:28932628
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014;27:1–7. doi:10.1016/j.coi.2013.12.005. PMID:24413387
   PubMed Web of Science ®Google Scholar
• Aarntzen EH, De Vries IJ, Lesterhuis WJ et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res. 2013;73:19–29. doi:10.1158/0008-5472.CAN-12-1127. PMID:23087058
   PubMed Web of Science ®Google Scholar
• Bailey SR, Nelson MH, Himes RA, Li Z, Mehrotra S, Paulos CM. Th17 cells in cancer: the ultimate identity crisis. Front Immunol. 2014;5:276. doi:10.3389/fimmu.2014.00276. PMID:24987392
   PubMed Web of Science ®Google Scholar
• Guery L, Hugues S. Th17 Cell Plasticity and Functions in Cancer Immunity. Biomed Res Int. 2015;2015:314620. doi:10.1155/2015/314620. PMID:26583099
   PubMed Web of Science ®Google Scholar
• Martinez NE, Sato F, Kawai E, Omura S, Chervenak RP, Tsunoda I. Regulatory T cells and Th17 cells in viral infections: implications for multiple sclerosis and myocarditis. Future Virol. 2012;7:593–608. doi:10.2217/fvl.12.44. PMID:23024699
   PubMed Web of Science ®Google Scholar
• McCarthy MK, Zhu L, Procario MC, Weinberg JB. IL-17 contributes to neutrophil recruitment but not to control of viral replication during acute mouse adenovirus type 1 respiratory infection. Virology. 2014;456–457:259–67. doi:10.1016/j.virol.2014.04.008. PMID:24889245
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity. 2016;44:989–1004. doi:10.1016/j.immuni.2016.05.001. PMID:27192565
   PubMed Web of Science ®Google Scholar
• Blake SJ, Ching AL, Kenna TJ, Galea R, Large J, Yagita H, Steptoe RJ. Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment. PLoS One. 2015;10:e0119483. doi:10.1371/journal.pone.0119483. PMID:25741704
   PubMed Web of Science ®Google Scholar
• Fernandez-Poma SM, Salas-Benito D, Lozano T, Casares N, Riezu-Boj JI, Mancheño U, Elizalde E, Alignani D, Zubeldia N, Otano I, et al. Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy. Cancer Res. 2017;77:3672–84. doi:10.1158/0008-5472.CAN-17-0236. PMID:28522749
   PubMed Web of Science ®Google Scholar
• Tahtinen S, Blattner C, Vaha-Koskela M, Saha D, Siurala M, Parviainen S, Utikal J, Kanerva A, Umansky V, Hemminki A. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFalpha Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma. J Immunother. 2016;39:343–54. doi:10.1097/CJI.0000000000000144. PMID:27741089
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Obrist F et al. Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology. 2014;3:e29030. doi:10.4161/onci.29030. PMID:25083328
   PubMed Web of Science ®Google Scholar
• Santos JM, Havunen R, Siurala M, Cervera-Carrascon V, Tähtinen S, Sorsa S, Anttila M, Karell P, Kanerva A, Hemminki A. Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy. Int J Cancer. 2017;141(7):1458–68. doi:10.1002/ijc.30839. PMID:28614908
   PubMed Web of Science ®Google Scholar
• Zafar S, Parviainen S, Siurala M, et al. Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40 L as an enabler of dendritic cell therapy. Oncoimmunology. 2017;6:e1265717. doi:10.1080/2162402X.2016.1265717. PMID:28344872
   PubMed Web of Science ®Google Scholar
• Haabeth OA, Lorvik KB, Hammarstrom C, Donaldson IM, Haraldsen G, Bogen B, Corthay A. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun. 2011;2:240. doi:10.1038/ncomms1239. PMID:21407206
   PubMed Web of Science ®Google Scholar
• Thakur A, Schalk D, Sarkar SH, Al-Khadimi Z, Sarkar FH, Lum LG. A Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells. Cancer Immunol Immunother. 2012;61:497–509. doi:10.1007/s00262-011-1116-1. PMID:21971587
   PubMed Web of Science ®Google Scholar
• Muraille E, Leo O, Moser M. TH1/TH2 paradigm extended: macrophage polarization as an unappreciated pathogen-driven escape mechanism? Front Immunol. 2014;5:603. doi:10.3389/fimmu.2014.00603. PMID:25505468
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Kamigaki T, Yamashita K, Hori Y, Hasegawa H, Kuroda D, Moriyama H, Nagata M, Ku Y, Kuroda Y. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. Oncol Rep. 2009;22:337–43. PMID:19578774
   PubMed Web of Science ®Google Scholar
• Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol. 2009;183:4169–75. doi:10.4049/jimmunol.0901017. PMID:19767566
   PubMed Web of Science ®Google Scholar